Simplified Chinese
scroll down
30
2025-04
On April 29, the Beijing Municipal Conference on Commending Model Workers, Advanced Workers, and Exemplary Collectives was solemnly held at the Beijing Convention Center. With approval from the CPC Beijing Municipal Committee and the Beijing Municipal People’s Government, Nie Xiaoqi, Deputy General Manager of Minhai Biotechnology, was awarded the honorary title of “Beijing Model Worker for 2025.” This year’s commendation placed particular emphasis on recognizing knowledge-based, skill‑driven, and innovation‑oriented workers, focusing on the capital’s major strategic priorities and key industries. Thanks to his outstanding contributions in vaccine production and quality management, Mr. Nie emerged as one of the distinguished representatives honored in the pharmaceutical and healthcare sector. For many years, Mr. Nie has been deeply committed to vaccine industrialization and quality assurance, successively holding positions in production management…
14
2025-03
Recently, Li Aifang, a member of the Party Leadership Group and Vice Chair of the CPPCC Committee of Daxing District, Beijing, paid a visit to Beijing Minhai Biotechnology Co., Ltd. to offer guidance. She toured the company’s corporate exhibition hall and its international‑standard vaccine industrial base, and engaged in an in-depth discussion with Zheng Haifa, a member of the Daxing District CPPCC Committee and General Manager of Minhai Biotechnology. Li Aifang emphasized that vaccines are a vital industry, delivering significant social, innovative, and economic value. For decades, Minhai Biotechnology has remained steadfastly committed to the research, development, and production of human vaccines, making outstanding contributions on behalf of Daxing District to the nation’s efforts in preventing and controlling infectious diseases. Looking ahead, she expressed the hope that the company will continue to take root in Daxing, expand globally, and bring greater benefits to public health through more high‑quality, highly effective, and innovative vaccines. She also urged the company to set an industry‑leading example in Daxing, thereby helping to drive the robust growth of the region’s biopharmaceutical sector.
14
2025-03
On the afternoon of March 11, 2025, Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as “Minhai Bio”) and the Chongqing Center for Disease Control and Prevention (hereinafter referred to as “Chongqing CDC”) successfully held a cooperation and exchange meeting at Minhai Bio’s Internationalization Industrial Base for Novel Vaccines. The meeting was attended by senior company executives, including Zhang Huadong, Director of the Chongqing CDC; Ji Hengqing and Wang Qing, Deputy Directors; and Zheng Haifa, General Manager of Minhai Bio, along with Liu Jiankai, Executive Deputy General Manager and Director of the R&D Center. During the event, Minhai Bio’s heads of R&D and clinical operations presented the company’s development history, its innovative R&D capabilities, and the progress of clinical trials for key projects.
27
2025-01
Batch Release Status of the Company’s Products in 2025
The company's product 2025 annual batch issuance situation is as follows: Serial No. | Product Name | Batch ---|---|--- 1 | Diphtheria, Tetanus, Acellular Pertussis and Haemophilus influenzae type b Combined Vaccine | 4 batches 2 | 23-valent Pneumococcal Polysaccharide Vaccine | 0 batches 3 | 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (TT/DT) | 11 batches 4 | Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed | 12 batches 5 | Haemophilus influenzae Type b Conjugate Vaccine, Freeze-dried | 6 batches 6 | Rabies Vaccine (Human Diploid Cell), Freeze-dried | 21 batches 7 | Varicella Vaccine, Live | 27 batches Batch release announcements: https://bio.nifdc.org.cn/pqf/search.do?formAction=pqfGs Batch release announcements: https://bio.nifdc.org.cn/pqf/search.do?formAction=pqfGs
06
2025-01
Detailed Personal Achievements: Nie Xiaoqi is the Deputy General Manager of Beijing Minhai Biotechnology Co., Ltd. and currently serves as the company’s Head of Quality Management. He has previously held positions including Director of the Diphtheria–Tetanus–Pertussis Workshop in Vaccine Department II, Director of Vaccine Department IV, and Head of Production Management. During his tenure in the production system, he successfully facilitated the smooth market launch of eight products, including the Hib–DTP–IPV quadrivalent vaccine, the 23-valent pneumococcal vaccine, the 13-valent pneumococcal vaccine, and the human diploid cell‑derived rabies vaccine. As Head of Quality Management, he has organized a series of training programs on international regulatory requirements for GMP‑related personnel, invited WHO inspectors to provide advisory visits to the company, and recommended quality‑management professionals to attend major international conferences on quality management.
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%